Monte Rosa Therapeutics, Inc. Common Stock

GLUENASDAQUSD
16.37 USD
0.99 (5.70%)AT CLOSE (11:59 AM EDT)
16.76
0.39 (2.38%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
16.76
0.39 (2.38%)
🔴Market: CLOSED
Open?$17.46
High?$17.80
Low?$16.25
Prev. Close?$17.36
Volume?950.3K
Avg. Volume?778.6K
VWAP?$16.79
Rel. Volume?1.22x
Bid / Ask
Bid?$15.99 × 100
Ask?$17.00 × 800
Spread?$1.01
Midpoint?$16.50
Valuation & Ratios
Market Cap?1.4B
Shares Out?84.5M
Float?49.3M
Float %?75.7%
P/E Ratio?N/A
P/B Ratio?2.65
EPS?-$1.54
Dividend?0.00%
Ex-Dividend?N/A

Shares of Monte Rosa Therapeutics, Inc. Common Stock (GLUE) are trading at $16.37. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. GLUE is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Employees
161
Market Cap
1.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-06-24
Address
321 HARRISON AVENUE
BOSTON, MA 02118
Phone: 617-949-2643
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-1/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
78
Momentum?
3
Short Sent.?
10
Piotroski F-Score?1/9Weak
Altman Z-Score?3.26Safe
Confidence?53%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?30.34%Squeeze Risk
Short Interest?15.0M
Days to Cover?20.6
Free Float49.3M
Avg Daily Volume725.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?9.54Strong
Quick Ratio?9.54Strong
Cash Ratio?2.25Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
61
2.65CHEAP
P/S?
Peers
100
S&P
3
32.20HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-8.7CHEAP
EV/Sales?
Peers
100
S&P
3
28.47HIGH
Returns & Efficiency
ROE?
S&P
7
-24.9%WEAK
ROA?
S&P
3
-17.7%WEAK
Cash Flow & Enterprise
FCF?$-19656000
Enterprise Value?$1.2B
Fundamentals ratios updated end of day